Target intelligence / Profile preview

T cell receptor beta joining 1-6 (TRBJ1-6)

Target
TRBJ1-6
Molecular classification
Joining segment gene component (of T cell receptor beta locus), Gene (not a typical therapeutic target class), Other (Somatic recombination gene segment)
01

Overview

T cell receptor beta joining 1-6 (TRBJ1-6) is a gene segment within the T cell receptor (TCR) beta locus, specifically one of the joining regions (J segments) that participate in the V(D)J recombination process essential for generating the diversity of the T cell receptor repertoire in human T lymphocytes[1][2][4][6]. This joining segment is not a standalone receptor or protein product but forms part of the coding sequence for the T cell receptor beta chain, which is critical for antigen recognition as part of the adaptive immune response[2][4][5]. The gene is located within the TRB locus on chromosome 7q34 and is predicted to be involved in the adaptive immune response as it is incorporated into the mature TCR expressed on the surface of T cells after proper recombination events[4][6]. While absolutely essential for the creation of functional TCR diversity, TRBJ1-6 is not itself a drug target or a receptor suitable for direct therapeutic targeting, but rather an essential germline gene segment necessary for tumor recognition, infection response, and immune homeostasis[2][4][6]. Changes or deletions in this and other J segments can affect repertoire diversity, but there are no direct associations with specific drugs, mechanisms of action, or biomarker applications for TRBJ1-6 individually.

Other names
TRBJ1-6TRBJ16TCRBJ1S6TJB16
02

Biological functions

Component of T cell receptor recombinationContributes to immune recognition diversityRequired for V(D)J recombination in T lymphocytesIndirectly involved in T cell-mediated immune response
03

Disease associations

Other (Alterations can affect T-cell diversity, implication in immune repertoire diversity, but not a direct disease driver)
04

Safety considerations

Not a therapeutic target, so no direct drug-related safety concerns reported; changes in recombination have theoretical impacts on T cell function, but this is general to the TCR locus, not this segment specifically

Beyond the preview

Go deeper on T cell receptor beta joining 1-6 (TRBJ1-6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 1-6 (TRBJ1-6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call